இம்யூனோ புற்றுநோயியல் சேவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from இம்யூனோ புற்றுநோயியல் சேவை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In இம்யூனோ புற்றுநோயியல் சேவை Today - Breaking & Trending Today

Six-and-a-Half-Year Outcomes for Opdivo in Combination with Yervoy Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma

49% of patients treated with Opdivo
plus Yervoy
were alive at 6.5 years and 77% of these patients remained treatment-free
Data to be featured in an oral presentation during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Bristol Myers Squibb (NYSE: BMY) today announced new six-and-a-half-year data from CheckMate -067, a randomized, double-blind, Phase 3 clinical trial, demonstrating durable improvement in survival with first-line
Opdivo (nivolumab) plus
Opdivo monotherapy, versus
Yervoy alone, in patients with advanced melanoma. With a minimum follow-up of 6.5 years, median overall survival (OS) was 72.1 months with
Opdivo plus
Yervoy (95% CI: 38.2-NR), the longest reported median OS in a Phase 3 advanced melanoma trial, 36.9 months with ....

United States , South Korea , Nina Goworek , Gina Fusaro , Bristol Myers Squibb , Company Opdivo , American Society Of Clinical Oncology , Bristol Myers Squibb Company , Oncology Service , European Union , Pathogenesis Program , World Health Organization , Exchange Commission , Ono Pharmaceutical Co , Memorial Sloan Kettering Cancer Center , Clinical Oncology , Annual Meeting , Myers Squibb , Immuno Oncology Service , Human Oncology , Memorial Sloan Kettering Cancer , Bristol Myers , American Society , Better Future , Fatal Immune Mediated Adverse Reactions , Full Prescribing Information ,

To Improve Immunotherapy, Researchers Look to Shift Immune Cells' Access to Sugar | Memorial Sloan Kettering Cancer Center

Summary
New research from Memorial Sloan Kettering scientists suggests that a way to improve immunotherapy is by altering immune cells’ access to sugar.
Cancer cells and immune cells share something in common: They both love sugar.
Sugar is an important nutrient. All cells use sugar as a vital source of energy and building blocks. For immune cells, gobbling up sugar is a good thing, since it means getting enough nutrients to grow and divide for stronger immune responses. But cancer cells use sugar for more nefarious ends.
So, what happens when tumor cells and immune cells battle for access to the same supply of sugar? That’s the central question that Memorial Sloan Kettering researchers Taha Merghoub, Jedd Wolchok, and Roberta Zappasodi explore in a new study published February 15 in the journal ....

Taha Merghoub , Sloan Kettering , Roberta Zappasodi , Oncology Service , Ludwig Center , Pathogenesis Program , Parker Institute For Cancer Immunotherapy , Memorial Sloan Kettering , Jedd Wolchok , Immuno Oncology Service , Human Oncology , Parker Institute , Parker Institute Bridge Scholar , Weill Cornell , ஸ்லோன் கெட்டரிங் , புற்றுநோயியல் சேவை , லுட்விக் மையம் , பார்க்கர் நிறுவனம் க்கு புற்றுநோய் நோயெதிர்ப்பு சிகிச்சை , நினைவகம் ஸ்லோன் கெட்டரிங் , இம்யூனோ புற்றுநோயியல் சேவை , மனிதன் புற்றுநோயியல் , பார்க்கர் நிறுவனம் , பார்க்கர் நிறுவனம் பாலம் அறிஞர் , வெயில் கார்னெல் ,